Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction

Wei, Wang, Liyan, Zhang, Pavan K., Battiprolu, Arata, Fukushima, Khanh, Nguyen, Kenneth, Milner, Abhishek, Gupta, Tariq, Altamimi, Nikole, Byrne, Jun, Mori, Osama Abo, Alrob, Cory, Wagg, Natasha, Fillmore, Shao-hua, Wang, Dongming M., Liu, Angela, Fu, Jenny Yinglin, Lu, Mary, Chaves, Alykhan, Motani, John R., Ussher, Jeff D., Reagan, Jason R.B., Dyck, Gary D., Lopaschuk

JACC: Basic to Translational Science |

Alterations in cardiac energy metabolism after a myocardial infarction contribute to the severity of heart failure (HF). Although fatty acid oxidation can be impaired in HF, it is unclear if stimulating fatty acid oxidation is a desirable approach to treat HF. Both immediate and chronic malonyl coenzyme A decarboxylase inhibition, which decreases fatty acid oxidation, improved cardiac function through enhancing cardiac efficiency in a post–myocardial infarction rat that underwent permanent left anterior descending coronary artery ligation. The beneficial effects of MCD inhibition were attributed to a decrease in proton production due to an improved coupling between glycolysis and glucose oxidation.